GSK teams up with Google on bioelectronic medicines

GlaxoSmithKline is teaming up with Google's parent company Alphabet to create a new company focused on developing bioelectronic medicines.

The UK drugs giant is setting up a joint venture - Galvani Bioelectronics - with Alphabet division Verily Life Sciences to enable research, development and commercialisation of new products in this relatively new field, which involves the use of miniaturised, implantable devices to modify electrical signals that might help tackle chronic diseases.

Each of its parent companies will contribute existing intellectual property rights and an investment of up to £540 million over seven years, subject to successful completion of various discovery and development milestones, giving GSK a 55 percent stake and Verily a 45 percent share in the business.

Galvani will be headquartered in the UK at GSK's global R&D centre at Stevenage, with a second research hub at Verily's facilities in South San Francisco, and the firm will initially take on around 30 expert scientists, engineers and clinicians, as well as stream funds into a broad range of collaborations with both parent companies, academia and other R&D organisations.

Initial work will centre on establishing clinical proofs of principle in inflammatory, metabolic and endocrine disorders, including type II diabetes, where substantial evidence already exists in animal models; and developing associated miniaturised, precision devices.

"This agreement with Verily to establish Galvani Bioelectronics signals a crucial step forward in GSK's bioelectronics journey, bringing together health and tech to realise a shared vision of miniaturised, precision electrical therapies," noted Moncef Slaoui, GSK's Chairman of Global Vaccines. "Together, we can rapidly accelerate the pace of progress in this exciting field, to develop innovative medicines that truly speak the electrical language of the body."

Kris Famm, GSK's vice president of Bioelectronics R&D, will lead the new company.

Featured Posts
Recent Posts
Search By Tags

About and GNN

The Global Naming Network (GNN), headquartered in Geneva, is the world's largest network of independent naming and brand identity agencies.


With around 240 cooperating naming and branding specialists in 16  countries, from Beijing to New York and from Seoul to Paris, GNN works for clients ranging from large multinationals to small startups all over the world.

Pharmaceutical projects are coordinated from the GNN office in Amsterdam by the pharma naming specialists of Globrands.

The website is dedicated to our expertise and work for the health & pharma industry.


Please contact us for more information.


offices in 16 countries


creatives, strategists & consultants

GNN offices

China                     South Korea

France                   Italy
Germany               Japan

Netherlands          UK

India                      Singapore

Spain                     Canada

Switzerland          Russia

USA                       Dubai


projects successfully executed


home                           name to brand

health & pharma        people

regulatory                   test & submit

India                             FDA

work                             blog

clients                          contact


linguistic professionals worldwide

Globrands the name behind the brands

© 2020 by Globrands consultancy group

Herengracht 122, 1015 BT Amsterdam, the Netherlands

call +31206238555 or mail to  


  • White LinkedIn Icon